Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: John Bloxom who wrote (882)	5/7/1998 11:44:00 PM
From: Michael Greene	Read Replies (1) \| Respond to of 2135

John, The comment on production was very brief. Here is the URL news.com "The company is working on endostatin and another compound, angiostatin, shown to rid mice of tumors. EntreMed says it has developed a way to produce enough of the drugs -- which have to be grown through genetic engineering -- so they can be tested in humans." Michael

To: John Bloxom who wrote (882)	5/8/1998 12:14:00 AM
From: Michael Greene	Read Replies (1) \| Respond to of 2135

John, If you have not heard Dr. Holaday's interview on the Motley Fool today it may be worth your time. fool.com "...made remarkable discoveries, not only on how the drugs work but also in making large enough quantities to do preliminary scale-up manufacturing so that we can move very rapidly." Again, these remarks are not quantitative but it sounds like they have made good progress. This audio may only be available for a short time. I do not know if it is placed into an accessible archive. This particular comment was made about 60% of the way through the interview. Michael